Centessa Pharmaceuticals plc(CNTA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,858 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
CNTA Stock Analysis & AI Quality Score
Data updated 2026-09-10AI stock analysis and institutional research for Centessa Pharmaceuticals plc (CNTA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CNTA at 14.9/100 on a 32-signal composite quality model, placing it at rank #2,858 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of CNTA by reported 13-F value include Medicxi Ventures Management (Jersey) Ltd, Avoro Capital Advisors, Index Venture Life Associates VI Ltd, based on the most recent SEC filings. CNTA trades on the Nasdaq exchange and files with the SEC under CIK 1847903. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Centessa Pharmaceuticals plc directly from SEC EDGAR. Centessa Pharmaceuticals plc's 13F Pro composite quality score has ranged between 15 and 20 since 2026, currently 14.9 — a declining long-term trajectory across 21 quarterly and live scoring snapshots.
Revenue
Q1 2026
$0.00
Net Income
Q1 2026
$-79.2M
ROIC
Q1 2026
-53.4%
D/E Ratio
Q1 2026
0.23
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+16.2% YoYOperating Income
-3.3% YoYEPS (Diluted)
+29.1% YoYTotal Assets
+19.2% YoYTotal Debt
+1.1% YoYOp. Cash Flow
-36.4% YoYFree Cash Flow
-36.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $15.0M | $0.00 -100.0% | $6.9M | $0.00 | — | — |
| Net Income | $-197.5M +16.2% | $-235.8M -56.0% | $-151.1M +30.1% | $-216.2M +43.3% | $-381.1M -3473.8% | $-10.7M |
| Operating Income | $-207.7M -3.3% | $-201.1M -17.4% | $-171.3M +19.3% | $-212.3M +43.3% | $-374.1M -3483.2% | $-10.4M |
| EPS (Diluted) | $-1.46 +29.1% | $-2.06 -31.2% | $-1.57 +32.0% | $-2.31 +54.4% | $-5.07 | — |
| Total Assets | $687.5M +19.2% | $576.8M +60.1% | $360.2M -18.9% | $444.3M -29.4% | $629.6M +5273.7% | $11.7M |
| Total Debt | $110.1M +1.1% | $108.9M +43.9% | $75.7M +8.5% | $69.8M -7.8% | $75.7M +1245.3% | $5.6M |
| Operating Cash Flow | $-193.8M -36.4% | $-142.1M +11.4% | $-160.3M +20.0% | $-200.5M -48.4% | $-135.1M -1171.0% | $-10.6M |
| Free Cash Flow | $-194.2M -36.7% | $-142.1M +11.5% | $-160.5M +20.4% | $-201.7M -49.1% | $-135.3M -1172.8% | $-10.6M |
Get alerted when CNTA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Centessa Pharmaceuticals plc including:
Top Institutional Holders of CNTA
Medicxi Ventures Management (Jersey) Ltd
$792.9M19,963,157 shAvoro Capital Advisors LLC
$454.0M11,430,455 shIndex Venture Life Associates VI Ltd
$395.7M9,961,789 shADAGE CAPITAL PARTNERS GP, L.L.C.
$354.5M8,925,010 shPentwater Capital Management LP
$324.5M8,170,000 shFMR LLC
$272.2M6,852,047 shEcoR1 Capital, LLC
$238.3M6,000,000 shPERCEPTIVE ADVISORS LLC
$208.9M5,258,903 shCapital World Investors
$191.9M4,832,548 shFARALLON CAPITAL MANAGEMENT LLC
$191.0M4,809,000 sh
| Fund | Value | Shares |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | $792.9M | 19,963,157 |
| Avoro Capital Advisors LLC | $454.0M | 11,430,455 |
| Index Venture Life Associates VI Ltd | $395.7M | 9,961,789 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $354.5M | 8,925,010 |
| Pentwater Capital Management LP | $324.5M | 8,170,000 |
| FMR LLC | $272.2M | 6,852,047 |
| EcoR1 Capital, LLC | $238.3M | 6,000,000 |
| PERCEPTIVE ADVISORS LLC | $208.9M | 5,258,903 |
| Capital World Investors | $191.9M | 4,832,548 |
| FARALLON CAPITAL MANAGEMENT LLC | $191.0M | 4,809,000 |
Companies Similar to CNTA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Thermon Group Holdings, Inc.
Metagenomi Therapeutics, Inc.
Keros Therapeutics, Inc.
Sanara MedTech Inc.
SERA PROGNOSTICS, INC.
Xencor Inc
SANGAMO THERAPEUTICS, INC
Nano-X Imaging Ltd.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CNTA on your watchlist
Track score changes the day Centessa Pharmaceuticals plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CNTA a good stock to buy?
13F Pro's AI-powered analysis of Centessa Pharmaceuticals plc (CNTA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CNTA are available on the CNTA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CNTA is classified as a mid company.
Which hedge funds own CNTA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CNTA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Centessa Pharmaceuticals plc's investment landscape.